• L-Alanyl-L-Glutamine: From Nutrient to Assay Variable

  2026-09-03

  L-Alanyl-L-glutamine can be more than a nutritional supplement dipeptide: it can function as a carefully controlled experimental variable in barrier, stress, and inflammation studies. This article connects molecular handling, assay design, and evidence boundaries to improve interpretation of gastrointestinal research.

• IWR-1-endo: From Wnt Control to Translation

  2026-09-02

  A translational framework for using IWR-1-endo to interrogate Wnt/β-catenin biology, validate pathway dependence, and connect mechanistic experiments with cell-state-resolved disease models.

• Praeruptorin A Workflow for Ferroptosis Research

  2026-09-02

  Build mechanism-led workflows with Praeruptorin A, from Fe²⁺ screening and DMT1 validation to doxorubicin cardiomyopathy research. The same angular pyranocoumarin compound also supports comparative studies of intestinal barrier inflammation and tumor-cell invasion when concentration, vehicle, and timing are controlled.

• Silybin A for Silymarin Liver Research

  2026-09-01

  Build reproducible liver and cancer biology assays with chemically defined Silybin A rather than relying on extract-level attribution. This workflow combines DMSO handling, dose–response design, oxidative-stress and fibrosis endpoints, and a metastasis-focused assay strategy adapted cautiously from ERK/MMP1 research.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-09-01

  The reference study identifies CD44-mediated metabolic rewiring as a dependency of IDH-mutant leukemia, linking pentose phosphate pathway activity and NADPH production to sustained R-2HG synthesis. Its isogenic genetic models and combination experiments suggest that disrupting both mutant IDH activity and CD44-dependent metabolism may address vulnerabilities not fully controlled by IDH inhibition alone.

• Nanocarrier-Mediated dsRNA Transdermal Delivery

  2026-08-31

  Guan and colleagues investigate how star cationic polymer nanocarriers help double-stranded RNA cross the insect cuticle, focusing on wax-layer disruption, improved wetting, and reduced resistance at the chitin layer. The study provides a mechanistic framework for noninvasive transdermal RNA interference delivery while also clarifying which barriers must be addressed in future formulations.

• Angiotensin II: From Pressor Signal to Fibrosis

  2026-08-31

  Angiotensin II is more than a hypertension stimulus: it can connect receptor signaling with inflammatory and fibrotic assay design. This guide uses renal fibrosis evidence to build a practical framework for vascular, renal, and remodeling studies.

• PX-478 2HCl: A Translational Hypoxia Strategy

  2026-08-30

  PX-478 2HCl provides a pharmacological route to interrogate HIF-1α across tumor hypoxia, radiation response, and ischemic microenvironments. This thought-leadership perspective connects product evidence with emerging metabolic and inflammatory biology while defining practical validation strategies and translational limits.

• Ouabain Workflows for Na+/K+-ATPase Assays

  2026-08-29

  Ouabain enables controlled interrogation of Na+/K+-ATPase activity, sodium–calcium coupling, and cardiotonic steroid physiology across cell and animal studies. This practical guide separates pump inhibition from secondary growth or death effects so researchers can build more informative ion-transport, cardiovascular, and myocardial infarction experiments.

• Ceruletide: Reproducible Pancreatic Models

  2026-08-28

  A scenario-driven guide to using Ceruletide (SKU B8465) in pancreatic function research, gastrointestinal physiology studies, and injury-related cell assays. It covers solvent compatibility, controls, assay interpretation, storage, and practical criteria for selecting a reliable Ceruletide supplier.

• Pcbp1, Mitochondria, and B-Cell Antibody Responses

  2026-08-28

  The reference study identifies the RNA-binding protein Pcbp1 as a posttranscriptional regulator of mitochondrial integrity, protein translation, and humoral immunity in B cells. Its mechanistic link to Fdxr, mitochondrial complex I, and germinal center function provides a framework for interpreting how metabolic defects can limit antibody production.

• OCT2 and MATE1 Inhibition by Antiemetic Drugs

  2026-08-27

  George and colleagues developed a comparative in vitro framework to determine how five 5-HT3 receptor antagonists interfere with the renal organic cation transport system formed by OCT2 and MATE1. The study identifies markedly different inhibitor profiles across the two transporters and shows that transporter inhibition can increase intracellular probe accumulation, providing a mechanistic basis for investigating renal drug–drug interactions.

• Pazopanib (GW-786034) Research Workflows

  2026-08-27

  Build reproducible angiogenesis, receptor-signaling, and tumor-cell response assays with Pazopanib (GW-786034), a multi-targeted RTK inhibitor suited to mechanism-focused cancer research. This workflow also translates ATRX-deficient glioma findings into practical sensitivity testing and combination experiments.

• Nanoparticle-Enhanced RNAi in Bemisia tabaci

  2026-08-26

  A 2026 study developed a C60/alkylpolyglucoside nanocarrier to improve dsRNA delivery against the whitefly Bemisia tabaci. Targeting btCHS and btG6PI, the system strengthened gene silencing and reduced insect survival, while also highlighting the need for careful validation beyond controlled tobacco-plant experiments.

• Sulfisomidine for Reliable Cell Assays

  2026-08-26

  Learn how Sulfisomidine (SKU BA1099) can support reproducible antibacterial, hPON1, enzyme kinetics, and cell viability workflows. This scenario-based guide covers concentration design, solvent compatibility, data interpretation, and practical supplier selection.

557 records 6/38 page Previous Next First page 上5页 678910 下5页 Last page